Pharmacologic Treatments for COVID-19

During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2

Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.

PDDS 2022 Speakers
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Alena Korbut

Alena Korbut

IHS/Cherokee Nation, United States
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Victoria Demina

Victoria Demina

NEUWAY Pharma GmbH, Germany
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Samir Haddouchi

Samir Haddouchi

Sotax Pharma Services, France
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Miroslav Radenkovic

Miroslav Radenkovic

University of Belgrade, Serbia
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Mirjana B. Colovic

Mirjana B. Colovic

University of Belgrade, Serbia
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Madhav Bhatia

Madhav Bhatia

University of Otago, New Zealand

Submit your abstract Today

Watsapp